Event JSON
{
"id": "f19c8a1be3f8a0323ab833c2355ce95208e399e6befd68b361fcd0ea45bddb58",
"pubkey": "b8f79cff66b2e593b08a5eba662e9dcbf3b626d5652e61b3b8cd8950a7733a38",
"created_at": 1734721151,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/novo-obesity-shot-shortfall-shows-180947135.html"
],
[
"subject",
"Novo’s Obesity Shot Shortfall Shows Danger of Promising Too Much"
],
[
"published_at",
"1734718187"
],
[
"image",
"https://s.yimg.com/ny/api/res/1.2/F9sfHLtHBOL1m2e5iyfLJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03Mjg-/https://media.zenfs.com/en/bloomberg_technology_68/b990977e787c6af4b364125015202ba9"
],
[
"p",
"b8f79cff66b2e593b08a5eba662e9dcbf3b626d5652e61b3b8cd8950a7733a38",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://s.yimg.com/ny/api/res/1.2/F9sfHLtHBOL1m2e5iyfLJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03Mjg-/https://media.zenfs.com/en/bloomberg_technology_68/b990977e787c6af4b364125015202ba9"
],
[
"t",
"Technology:perspective"
],
[
"summary",
"Novo Nordisk's CagriSema, expected to help patients lose 25% or more of their body weight, failed to meet its own bar, with patients losing only 20.4% in a study. The disappointing results led to a 27% drop in Novo's shares, wiping out $120 billion from its market value. The company's failure to meet expectations puts pressure on it to find ways to beef up its pipeline of experimental medicines."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqhrmeelmxktje8vy2t6axvt5ae0emvfk4v5hxrvaceky4pfmn8guq4j834n\nhttps://s.yimg.com/ny/api/res/1.2/F9sfHLtHBOL1m2e5iyfLJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03Mjg-/https://media.zenfs.com/en/bloomberg_technology_68/b990977e787c6af4b364125015202ba9\n\nhttps://finance.yahoo.com/news/novo-obesity-shot-shortfall-shows-180947135.html",
"sig": "f4aed807e0ab7d7e9c9a094f58c46892975e9308c63230c6442981ddf4c37d37480fcc165b7a950408f14ad9901b8e66147396440cfdac01589c99a65bbf2ddc"
}